BOSTON, July 17, 2018 /PRNewswire/ -- NanoView Biosciences, ("NanoView" or the "Company"), an emerging leader in commercializing high value exosome-associated products, today announced that Jerry Williamson has been named as the Company's new Chief Executive Officer effective July 1, 2018, and continues as a member of the Board of Directors. Mr. Williamson succeeds David Freedman, Ph.D., Co-founder of NanoView, who will remain with the Company as Chief Operating Officer.
Ian Ratcliffe, Managing Partner at Sands Capital Ventures and member of the Board of Directors of NanoView, said, "On behalf of the Board, we are excited to have Jerry at the helm of NanoView. His accomplishments in product development and commercialization of research tools and diagnostics are essential as the Company is poised to aggressively commercialize its highly innovative technology platform to detect and characterize exosomes." Mr. Ratcliffe added, "We thank Dr. Freedman for his founding management of NanoView. Along with co-founder George Daaboul, Ph.D., the Company's Chief Scientific Officer, we now have an extremely strong senior team to carry the company forward."
"Having served as Director on the Board of NanoView since early 2017, I have seen the power of the platform that David, George and their team have built," said Mr. Williamson. "I am honored and excited to lead the Company into the commercial phase of its first products. The markets for exosome detection and characterization are exploding and NanoView has the opportunity to rapidly emerge as a leading technology provider for basic research, and therapeutic and diagnostic development," added Mr. Williamson.
Jerry Williamson brings more than 30 years of commercial operations, business development and corporate management experience in the life science marketplace where he has held executive leadership roles responsible for value creation, growth and profitability. Most recently, Mr. Williamson was President and CEO of KEW Inc., a provider of next generation sequencing for comprehensive genomic profiling of cancer. Prior to KEW, he was President and CEO of Metamark Genetics, Inc., a molecular diagnostics company focused on prostate cancer. Mr. Williamson has held positions of senior leadership for Flagship Ventures; Genetix, Ltd. which was sold to Danaher; Biacore, Inc. which was sold to GE Life Sciences; and Pyrosequencing, Inc. He received a BS degree in Biochemistry from the University of Vermont and holds an MBA degree from Boston University.
About NanoView
nanoView Diagnostics Inc. (dba NanoView Biosciences), is developing proprietary products that support research, translation and delivery of precision medicine. The Company was founded on a novel technology platform that uniquely identifies and characterizes exosomes. Our high-throughput, cost-effective analysis solutions enable life science researchers to better understand the biological role of exosomes and how to utilize them as biomarkers to provide improved insight for how diseases are diagnosed, treated and monitored.
Learn more at www.nanoviewbio.com
Company and Media Contact:David Freedman, Ph.D.Chief Operating [email protected]
Advertisement
Ian Ratcliffe, Managing Partner at Sands Capital Ventures and member of the Board of Directors of NanoView, said, "On behalf of the Board, we are excited to have Jerry at the helm of NanoView. His accomplishments in product development and commercialization of research tools and diagnostics are essential as the Company is poised to aggressively commercialize its highly innovative technology platform to detect and characterize exosomes." Mr. Ratcliffe added, "We thank Dr. Freedman for his founding management of NanoView. Along with co-founder George Daaboul, Ph.D., the Company's Chief Scientific Officer, we now have an extremely strong senior team to carry the company forward."
Advertisement
"Having served as Director on the Board of NanoView since early 2017, I have seen the power of the platform that David, George and their team have built," said Mr. Williamson. "I am honored and excited to lead the Company into the commercial phase of its first products. The markets for exosome detection and characterization are exploding and NanoView has the opportunity to rapidly emerge as a leading technology provider for basic research, and therapeutic and diagnostic development," added Mr. Williamson.
Jerry Williamson brings more than 30 years of commercial operations, business development and corporate management experience in the life science marketplace where he has held executive leadership roles responsible for value creation, growth and profitability. Most recently, Mr. Williamson was President and CEO of KEW Inc., a provider of next generation sequencing for comprehensive genomic profiling of cancer. Prior to KEW, he was President and CEO of Metamark Genetics, Inc., a molecular diagnostics company focused on prostate cancer. Mr. Williamson has held positions of senior leadership for Flagship Ventures; Genetix, Ltd. which was sold to Danaher; Biacore, Inc. which was sold to GE Life Sciences; and Pyrosequencing, Inc. He received a BS degree in Biochemistry from the University of Vermont and holds an MBA degree from Boston University.
About NanoView
nanoView Diagnostics Inc. (dba NanoView Biosciences), is developing proprietary products that support research, translation and delivery of precision medicine. The Company was founded on a novel technology platform that uniquely identifies and characterizes exosomes. Our high-throughput, cost-effective analysis solutions enable life science researchers to better understand the biological role of exosomes and how to utilize them as biomarkers to provide improved insight for how diseases are diagnosed, treated and monitored.
Learn more at www.nanoviewbio.com
Company and Media Contact:David Freedman, Ph.D.Chief Operating [email protected]
View original content:http://www.prnewswire.com/news-releases/nanoview-biosciences-appoints-jerry-williamson-as-chief-executive-officer-300680684.html
SOURCE NanoView Biosciences
